Deirdre Cohen, MD
Hematology & Oncology · New York, NYNPI 1275759318
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Astellas Pharma US Inc at 54.2% of the total. 2025 is the largest year on record at $16,051, 6.5 times the $2,463 reported in 2020.
Across 42 payments — averaging $948.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$22K
- Incyte Corporation$4K
- Fosun Pharma USA Inc.$3K
- Seagen Inc.$2K
- Eli Lilly$2K
- Eisai Inc.$2K
- plus $6K from 11 others
Across 136 payments — averaging $22,742 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.1M
- Eisai Inc.$219K
- E.r. Squibb & Sons, L.L.C.$208K
- GSK$181K
- Janssen Research & Development, LLC$74K
- Mirati Therapeutics, Inc.$65K
- plus $250K from 9 others
What the payments were for
- Consulting fees$18,17946%
- Speaking & faculty fees$17,36344%
- Travel & lodging$2,6747%
- Food & beverage$1,6214%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 17 | $21,608 |
| Incyte Corporation | 5 | $4,436 |
| Fosun Pharma USA Inc. | 2 | $2,587 |
| Seagen Inc. | 1 | $1,750 |
| Eli Lilly | 2 | $1,665 |
| Eisai Inc. | 2 | $1,635 |
| Beigene USA, Inc. | 1 | $1,625 |
| Taiho Oncology, Inc. | 1 | $1,563 |
| AstraZeneca | 2 | $1,366 |
| Bayer | 2 | $921 |
| Foundation Medicine, Inc. | 1 | $229 |
| Biontech SE | 1 | $153 |
| Ipsen Biopharmaceuticals, Inc | 1 | $92 |
| Novartis | 1 | $90 |
| Beone Medicines USA, Inc. | 1 | $72 |
| Tempus AI, Inc | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,837 in reported general payments places this provider in the 85th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Olanzapine | 23 | $187 |
| Ondansetron Hcl | 20 | $104 |
| Prochlorperazine Maleate | 13 | $103 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.